Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753897 | 0.91 | GABRA1 (0.42) | GABRA1GABRB2CYP3A4TSHR | |
| SCHEMBL7102166 | 0.75 | GABRA1 (0.55) | GABRA1GABRB2CYP3A4TSHR | |
| SCHEMBL10798784 | 0.69 | GABRA1 (0.42) | GABRA1GABRB2CYP3A4TSHR | |
| 1,4-Butanediol SCHEMBL15372833 | 0.69 | CYP3A4 (0.41) | GABRA1GABRB2CYP3A4TSHR | |
| SCHEMBL7626712 | 0.67 | CYP3A4 (0.42) | GABRA1GABRB2CYP3A4TSHR | |
| SCHEMBL11855962 | 0.65 | GABRA1 (0.50) | GABRA1GABRB2CYP3A4TSHRCA2 | |
| SCHEMBL29574102 | 0.65 | GABRA1 (0.75) | GABRA1GABRB2CYP3A4TSHR | |
| SCHEMBL754997 | 0.65 | GABRA1 (0.75) | GABRA1GABRB2CYP3A4TSHR | |
| SCHEMBL11697004 | 0.63 | GABRA1 (0.36) | GABRA1GABRB2CYP3A4TSHR | |
| SCHEMBL467385 | 0.62 | GABRA1 (0.57) | GABRA1GABRB2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633261-B2 | Polymer composites having particles with mixed organic modifications | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-01-21 | — | — | US | disclosed |
| US-8293812-B2 | Containing thermoplastic resin having solid particles dispersed throughout; controlling particle size; modulus; high tensile strength | The University of Queensland St. Lucia (AU) | 2012-10-23 | — | — | US | disclosed |
| US-20110060072-A1 | POLYMER COMPOSITES HAVING PARTICLES WITH MIXED ORGANIC MODIFICATIONS | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-03-10 | — | — | US | disclosed |
| US-20080281016-A1 | Polymer Composite | MILLER WASTE MILLS INC. DBA RTP COMPANY | 2008-11-13 | — | — | US | disclosed |
| WO-2006024068-A1 | POLYMER COMPOSITE | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060072-A1 | POLYMER COMPOSITES HAVING PARTICLES WITH MIXED ORGANIC MODIFICATIONS | PUF60, PCBP1, LCP1 | GABRA1 4073/4885GABRB2 4616/4885BCHE 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.